News Releases

April 15, 2019
Synlogic to Present Data from New Solid Oral Formulation Process at the 22nd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 15, 2019-- Synlogic, Inc. , (Nasdaq: SYBX) a clinical-stage drug discovery and development company applying synthetic biology to probiotics to develop novel living medicines, today announced that data from its program to develop solid oral formulations of...
April 9, 2019
Synlogic Appoints Scott Plevy M.D. as Chief Scientific Officer
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 9, 2019-- Synlogic, Inc . (Nasdaq: SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced the appointment of Scott Plevy , M.D., as Chief Scientific Officer. Dr....
April 2, 2019
Synlogic to Webcast Presentation at the 18th Annual Needham Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 2, 2019-- Synlogic (Nasdaq:SYBX) announced today that Aoife Brennan , M.B., B.Ch., Synlogic’s president and chief executive officer, will provide a corporate update at the 18th Annual Needham Healthcare Conference at 3:30 pm ET on Tuesday, April 9, 2019 , in...
March 13, 2019
Synlogic to Webcast Presentation at the Oppenheimer 29th Annual Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 13, 2019-- Synlogic (Nasdaq:SYBX) announced today that Caroline Kurtz , Ph.D., Synlogic’s Head of Metabolism, will provide a corporate update at Oppenheimer’s 29th Annual Healthcare Conference at 3:20 pm ET on Wednesday, March 20, 2019 , in New York City ....
March 12, 2019
Synlogic Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
– Ended 2018 with approximately $123 million in cash and investments, which provides runway through 2020 – – Clinical trial readouts expected in mid-2019 from two Synthetic Biotic ™ medicines and first IND application expected from Synlogic’s immuno-oncology platform in second half of 2019 – –...
March 6, 2019
Synlogic Announces Achievement of Milestone in Collaboration to Develop Synthetic Biotic™ Medicines to Treat Inflammatory Bowel Disease
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 6, 2019-- Synlogic, Inc ., (Nasdaq: SYBX) a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced the advancement of Synthetic Biotic medicines to the lead optimization stage in its...
March 5, 2019
Synlogic Announces Fourth Quarter and Full Year 2018 Conference Call and Webcast
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 5, 2019-- Synlogic, Inc. ( Nasdaq: SYBX ), a clinical stage company applying synthetic biology to probiotics to develop novel, living medicines, announced today that the Company will release its fourth quarter and full year 2018 financial results before the...
February 28, 2019
Synlogic to Present at Investor Conferences in March
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 28, 2019-- Synlogic (Nasdaq:SYBX) announced today that Aoife Brennan , M.B., B.Ch., Synlogic’s president and chief executive officer, will present at the following upcoming investor conferences: Chardan’s 1 st Annual Microbiome Medicines Summit at 2:05pm ET...
February 20, 2019
Synlogic to Webcast Presentation at the SVB Leerink 8th Annual Global Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 20, 2019-- Synlogic (Nasdaq:SYBX) announced today that Aoife Brennan , M.B., B.Ch., Synlogic’s president and chief executive officer, will provide a corporate update at the SVB Leerink 8th Annual Global Healthcare Conference at 1:30 pm ET on Thursday,...
February 12, 2019
Synlogic Appoints Patricia N. Hurter, Ph.D. to Board of Directors
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 12, 2019-- Synlogic, Inc. , (Nasdaq:SYBX) a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced the appointment of Patricia N. Hurter , Ph.D., Senior Vice President of Pharmaceutical...
January 16, 2019
Science Translational Medicine Publishes First-in-Human Clinical Data and Supporting Preclinical Data for SYNB1020, Synlogic’s Synthetic Biotic™ Medicine in Development as a Potential Treatment for Hyperammonemia
–Phase 1 clinical trial to evaluate safety and tolerability of SYNB1020 in healthy volunteers demonstrated safety, clearance and proof of mechanism– – Data from ongoing Phase 1b/2a clinical trial in patients with cirrhosis and elevated ammonia expected mid-2019 – CAMBRIDGE, Mass....
January 3, 2019
Synlogic Progresses Clinical and Preclinical Pipeline and Outlines 2019 Catalysts
– Presentation of topline clinical data from studies of Synthetic Biotic™ medicines, SYNB1020 and SYNB1618, in patients expected mid-2019 – – Investigational New Drug (IND) application for SYNB1891, Synlogic’s first immuno-oncology program, expected in 2H2019 – CAMBRIDGE, Mass....
Displaying 37 - 48 of 115